Investors 2016-12-09T07:33:03+00:00

Dimerix is discovering and developing important new drug therapies for major unmet medical needs identified using our proprietary cell-based drug discovery platform.

At the same time, our transformative drug discovery technology, known as Receptor-HIT, provides Dimerix with ongoing revenues from global industry partners seeking to improve their own programs.

Our vision is to positively improve human health through the creation of new treatments for major unmet medical needs.

Latest ASX Announcements

Dimerix Shareholder Presentation and Q&A with CEO

MELBOURNE, Australia, 16th May 2017: Dimerix Limited (ASX: DXB) is on schedule to release final data from its Phase 2 Part A study in Chronic Kidney Disease in July. Investors are invited to attend a [...]

Appointment of Hugh Alsop as Non-Executive Director

Dimerix Limited (ASX:DXB) today announced the appointment of Mr Hugh Alsop as Non-Executive Director. Read our full announcement here.

Shareholders: roll up to an investor meeting near you

Ahead of the clinical trial results to be released mid-year, Dimerix CEO Kathy Harrison will be running shareholder information sessions in most Australian capital cities. Dates for Perth, Melbourne, Adelaide and Sydney are available here. [...]

ASX announcement – Proactive investor presentation

To read the announcement and the presentation click here

Read More

Media Coverage

Invitation to Gold Coast Investment Showcase

Read this invitation here.

Change of Venue for Sydney Shareholder Q&A

Read this announcement here. 

NDF Research Analyst Report March 2017

Read the report on their website. 

Read More

Stock Quote

View stock price: ASX Stock Price

Email Alert

subscribe to news updates